热门资讯> 正文
胰腺治疗数据导致免疫工程股票飙升45%
2024-09-13 05:58
- Immuneering (NASDAQ:IMRX) stock rocketed 45% post-market Thursday after the company reported positive Phase 2a data for its drug candidate IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel as a first-line treatment for pancreatic cancer.
- The drug developer said the study observed complete or partial responses in the first two out of five patients to date, with an overall initial response rate of 40% and disease control rate of 80%, according to a statement.
- Immuneering said it expects to have additional data by the end of the year.
More on Immuneering
- Seeking Alpha’s Quant Rating on Immuneering
- Historical earnings data for Immuneering
- Financial information for Immuneering
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
